Evaluation of FGF-23 suppressibility by Calcitonin in Healthy Men- pilot study

Evaluation of FGF-23 suppressibility by Calcitonin in Healthy Men- pilot study - FGF-23 suppressibility by Calcitonin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON32168

Enrollment

Registered

2008-05-09

Start date

2008-04-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fysiologische regulatie fosfaat houshouding phosphate homeostasis phosphate regulation

Interventions

All subjects are examined on two occasions, once after exposure to placebo 1 ml NaCl 0.9% subcutaneously, and once following 1 ml calcitonin 200 IU/ml subcutaneously.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy, male sex, age 20-55 years

Exclusion criteria

Exclusion criteria: Serum creatinin > 100 micromol/L, or glomerular filtration rate

Design outcomes

Primary

Measure	Time frame
A significant change in de serum FGF-23 levels in response to a single subcutaneous injection of calcitonin 200 IU.	—

Secondary

Measure	Time frame
De serum levels for calcium, parathormon and vitamin D.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)